Ikarian Capital’s Altimmune ALT Stock Holding History

Ikarian Capital’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-677,300	Closed	-$2.86M	–	128
2023 Q1	$2.86M	Buy	677,300 +403,868	+148%	+$4.8M	0.65%	47
2022 Q4	$4.5M	Sell	273,432 -198,622	-42%	-$2.23M	1.09%	30
2022 Q3	$6.03M	Sell	472,054 -425,305	-47%	-$6.28M	1.2%	31
2022 Q2	$10.5M	Buy	+897,359	New	+$5.53M	1.91%	16
2021 Q2	–	Sell	-181,941	Closed	-$2.57M	–	215
2021 Q1	$2.57M	Buy	181,941 +106,496	+141%	+$1.72M	0.09%	184
2020 Q4	$851K	Sell	75,445 -38,323	-34%	-$452K	0.04%	180
2020 Q3	$1.5M	Sell	113,768 -51,232	-31%	-$1.02M	0.11%	123
2020 Q2	$1.77M	Buy	+165,000	New	+$906K	0.14%	109

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ikarian Capital's ALT Position: Q2 2023 in Review

Ikarian Capital sold out of Altimmune (ALT) in Q2 2023, closing a stake of 677,300 shares — an estimated $2.86M sold.

Ikarian Capital first reported a position in ALT in Q2 2020 and held it in 8 quarters. The position peaked at $10.5M in Q2 2022. 120 funds tracked by Wall St. Rank hold ALT as of Q2 2023.

Ikarian Capital reported no remaining Altimmune position as of Q2 2023 after selling out during the quarter.
Ikarian Capital sold 677,300 Altimmune shares in Q2 2023, an estimated $2.86M.
Ikarian Capital first reported a position in Altimmune in Q2 2020 and held it in 8 quarters.
Ikarian Capital's Altimmune position peaked at $10.5M in Q2 2022.
120 funds tracked by Wall St. Rank held Altimmune as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.